文献速递脑血管病神经重症与神经感染

低水平小窝蛋白-1预测急性缺血性卒中患者溶栓治疗后症状性出血

Low Levels of Caveolin-1 Predict Symptomatic Bleeding After Thrombolytic Therapy in Patients With Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2018-04-30

研究纳入133例首次半球卒中且症状发作4.5小时内接受r-tPA治疗的患者,在给药前及给药后2、24、72小时检测血清小窝蛋白-1水平,并与40例健康对照比较。结果显示,基线小窝蛋白-1水平≤0.17 ng/mL独立预测症状性出血转化(OR 11.6,95%CI 11.3-102.8,P=0.027),但样本量小,需进一步研究验证。

要点

  • 基线小窝蛋白-1≤0.17 ng/mL预测症状性出血转化灵敏度86%、特异度65%。
  • 校正混杂因素后,小窝蛋白-1≤0.17 ng/mL独立预测症状性出血转化(OR 11.6)。
  • 患者基线小窝蛋白-1水平高于健康对照(0.24 vs 0.07 ng/mL,P<0.000)。

核心结论

  • 低血清小窝蛋白-1水平是r-tPA给药后症状性出血转化的独立预测因素。
  • 因样本量小,需进一步研究验证这些数据。

研究设计与样本

  • 研究纳入133例首次半球卒中且症状发作4.5小时内接受r-tPA治疗的患者,并与40例健康对照比较。
  • 在r-tPA给药前及给药后2、24、72小时检测血清小窝蛋白-1水平。
  • 卒中后24小时通过头颅计算机断层扫描评估并分类出血转化,伴神经功能恶化者定义为症状性出血转化。

主要发现

  • 患者基线小窝蛋白-1水平高于健康对照(0.24 [0.17-0.40] vs 0.07 [0.0-0.20] ng/mL,P<0.000)。
  • 26例(19.5%)患者发生出血转化,其中7例(5.3%)为症状性出血转化。
  • 脑实质出血-2型和症状性出血转化患者基线小窝蛋白-1水平低于其余患者(分别为0.08 [0.04-0.19] vs 0.26 [0.14-0.40] ng/mL,P=0.019;0.08 [0.02-0.17] vs 0.26 [0.13-0.41] ng/mL,P=0.019)。
  • 脑实质出血-2型和症状性出血转化患者小窝蛋白-1水平在最初72小时内保持稳定,而其余患者在此期间水平下降。
  • 小窝蛋白-1≤0.17 ng/mL预测症状性出血转化的能力最高(灵敏度86%,特异度65%,阴性预测值99%,阳性预测值12%)。

局限性

  • 因样本量小,需进一步研究验证这些数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Experimental models of cerebral ischemia demonstrate that the decrease in the caveolin-1 membrane protein results in an increase in endothelial permeability. Because this phenomenon is responsible for hemorrhagic transformation (HT) after cerebral ischemia, we aimed to determine whether caveolin-1 levels may predict bleeding after recombinant tissue-type plasminogen activator (r-tPA) administration in patients with acute stroke. METHODS: We studied 133 patients with a first hemispheric stroke treated with r-tPA within 4.5 hours of symptom onset. HT was evaluated and classified on cranial computed tomography at 24 hours and was considered as symptomatic HT (sHT) if associated with neurological deterioration. Serum caveolin-1 levels were analyzed before and at 2, 24, and 72 hours post-r-tPA administration in patients and in 40 healthy controls. RESULTS: Baseline caveolin-1 levels were higher in patients than controls (0.24 [0.17-0.40] versus 0.07 [0.0-0.20] ng/mL; P<0.000). Twenty six (19.5%) patients had HT, which was symptomatic in 7 (5.3%). Patients with parenchymal hemorrhage-2 and sHT had lower baseline caveolin-1 levels than the rest of patients (0.08 [0.04-0.19] versus 0.26 [0.14-0.40]; P=0.019 and 0.08 [0.02-0.17] versus 0.26 [0.13-0.41]; P=0.019, respectively). The levels remained stable in the first 72 hours in patients with parenchymal hemorrhage-2 and sHT, whereas in the rest of patients levels decreased in this time. Caveolin-1 levels ≤0.17 ng/mL had the highest predictive capacity of sHT (86% sensitivity, 65% specificity, 99% negative predictive value, 12% positive predictive value). After adjustment for confounders, caveolin-1 levels ≤0.17 ng/mL independently predicted sHT (odds ratio, 11.6; 95% confidence interval, 11.3-102.8; P=0.027). CONCLUSIONS: Low serum levels of caveolin-1 are an independent predictor of sHT after r-tPA administration. Because of the small sample size, further research is needed to validate these data.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Castellanos M, van Eendenburg C, Gubern C, et al. Low Levels of Caveolin-1 Predict Symptomatic Bleeding After Thrombolytic Therapy in Patients With Acute Ischemic Stroke. Stroke. 2018. PMID: 29712879. doi:10.1161/STROKEAHA.118.020683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。